This book examines in detail the current treatment options for first-line, relapsed, and refractory Hodgkin lymphoma and the management appropriate in special clinical circumstances, including in the elderly, pregnant women, and those with lymphocyte-predominant disease. Careful attention is devoted to the emerging individually tailored treatment strategies that are especially appealing given their potential to reduce early and late treatment side effects in this generally young patient population. In addition, clear guidance is provided on the management of Hodgkin survivors. Other topics addressed include epidemiology, pathogenesis, the role of the microenvironment, initial clinical evaluation, imaging diagnosis, use of staging systems, and prognostic factors. The second edition of Hodgkin Lymphoma: A Comprehensive Overview has been revised and updated by the key opinion leaders to reflect recent progress in the field. It will be of great value to hematologists, oncologists, and all others with an interest in Hodgkin lymphoma.
Part I: From Hodgkin’s disease to Hodgkin Lymphoma: Epidemiology.- The role of viruses in the genesis of Hodgkin Lymphoma.- Pathology and molecular pathology of Hodgkin Lymphoma.- Microenvironment, cross-talk and immune escape mechanisms.- What will we learn from Genomics and Proteomics in Hodgkin Lymphoma? Part II: Diagnosis and treatment:Clinical evaluation.- Functional imaging.- Prognostic factors.- Principles of radiation techniques in Hodgkin Lymphoma.- Principles of chemotherapy in Hodgkin Lymphoma.- Treatment of early favorable Hodgkin Lymphoma.- Treatment of early unfavorable Hodgkin Lymphoma.- Treatment of advanced-stage Hodgkin Lymphoma.- Relapsed and refractory Hodgkin Lymphoma.- Paediatric Hodgkin Lymphoma. Part III: Special Clinical Situations: Lymphocyte-predominant Hodgkin Lymphoma.- The management of Hodgkin Lymphoma during pregnancy.- The management of HIV-Hodgkin Lymphoma.- The management of elderly patients with Hodgkin Lymphoma.- Allogeneic transplantation for relapsed of Hodgkin Lymphoma.- Targeting CD 30.- Other new agents for patients with Hodgkin Lymphoma. Part IV: Survivorship: Quality of Life in Hodgkin Lymphoma.- Second malignancy risk after treatment of Hodgkin Lymphoma.- Cardiovascular and pulmonary late effects.- Gonadal dysfunction and fertility preservation in Hodgkin Lymphoma patients.